Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.

Authors: Meric-Bernstam, Funda, Alhalabi, Omar, Lisberg, Aaron, Drakaki, Alexandra, Garmezy, Benjamin, Kogawa, Takahiro, Spira, Alexander I., Salkeni, Mohamad Adham, Gao, Xin, Tolcher, Anthony W., Bhave, Manali A., Doroshow, Deborah Blythe, Hoffman-Censits, Jeannie, Klauss, Gunnar, Kaga, Yoshiaki, Kakurai, Yasuyuki, Kojima, Takahiro

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p663-663, 242p

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

Authors: Cleary, James M., Calvo, Emiliano, Moreno, Victor, Juric, Dejan, Shapiro, Geoffrey I., Vanderwal, Carol Ann, Hu, Beibei, Gifford, Maryella, Barch, David, Roberts-Rapp, Lisa, Ansell, Peter J., Xiong, Hao, Ocampo, Christopher, Tolcher, Anthony W.

Source: Investigational new drugs. 38(5):1483-1494

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100171295396.0x000001&indx=1&recIds=ETOCvdc_100171295396.0x000001

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.

Authors: Bardia, Aditya, Krop, Ian E., Kogawa, Takahiro, Juric, Dejan, Tolcher, Anthony W., Hamilton, Erika P., Mukohara, Toru, Lisberg, Aaron, Shimizu, Toshio, Spira, Alexander I., Tsurutani, Junji, Damodaran, Senthil, Papadopoulos, Kyriakos P., Greenberg, Jonathan, Kobayashi, Fumiaki, Zebger-Gong, Hong, Wong, Rie, Kawasaki, Yui, Nakamura, Tadakatsu, Meric-Bernstam, Funda

Source: Journal of Clinical Oncology; 7/1/2024, Vol. 42 Issue 19, p2281-2294, 17p

A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors

Authors: Rosen, Lee S., Wesolowski, Robert, Baffa, Raffaele, Liao, Kai-Hsin, Hua, Steven Y., Gibson, Brenda L., Pirie-Shepherd, Steven, Tolcher, Anthony W.

Source: Investigational new drugs. 38(1):120-130

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100127313078.0x000001&indx=1&recIds=ETOCvdc_100127313078.0x000001

Antibody drug conjugates: The dos and don'ts in clinical development

Authors: Tolcher, Anthony W.

Source: Pharmacology and therapeutics. 240

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100176642523.0x000001&indx=1&recIds=ETOCvdc_100176642523.0x000001

Improving combination cancer therapy: the CombiPlex® development platform

Authors: Tolcher, Anthony W, Mayer, Lawrence D

Source: Future oncology. 14(13):1317-1332

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100179211879.0x000001&indx=1&recIds=ETOCvdc_100179211879.0x000001

Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor–targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort.

Authors: Ulahannan, Susanna Varkey, Johnson, Melissa Lynne, Weiss, Mia C., Vandross, Andrae L., Vidal-Cardenas, Sofia Luz, Syed, Mustafa, Tolcher, Anthony W.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS237-TPS237, 235p

Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.

Authors: Ulahannan, Susanna Varkey, Johnson, Melissa Lynne, Weiss, Mia C., Vandross, Andrae L., Vidal-Cardenas, Sofia Luz, Syed, Mustafa, Tolcher, Anthony W.

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pTPS421-TPS421, 185p

Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.

Authors: Macarulla, Teresa, Yamamoto, Noboru, Tolcher, Anthony W., Hafez, Navid, Lugowska, Iwona, Ramlau, Rodryg, Geng, Junxian, Li, Jian, Teufel, Michael, Maerten, Angela, LoRusso, Patricia

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p487-487, 151p

Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy

Authors: Satsangi, Arpan, Roy, Sudipa S., Satsangi, Rajiv K., Tolcher, Anthony W., Vadlamudi, Ratna K., Goins, Beth, Ong, Joo L.

Source: In Biomaterials August 2015 59:88-101

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Blay, Jean-Yves, Pápai, Zsuzsanna, Tolcher, Anthony W, Italiano, Antoine, Cupissol, Didier, López-Pousa, Antonio, Chawla, Sant P, Bompas, Emmanuelle, Babovic, Nada, Penel, Nicolas, Isambert, Nicolas, Staddon, Arthur P, Saâda-Bouzid, Esma, Santoro, Armando, Franke, Fabio A, Cohen, Patrick, Le-Guennec, Solenn, Demetri, George D

Source: In The Lancet Oncology May 2015 16(5):531-540

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01.

Authors: Shimizu, Toshio, Sands, Jacob, Yoh, Kiyotaka, Spira, Alexander, Garon, Edward B., Kitazono, Satoru, Johnson, Melissa L., Meric-Bernstam, Funda, Tolcher, Anthony W., Yamamoto, Noboru, Greenberg, Jon, Kawasaki, Yui, Zebger-Gong, Hong, Kobayashi, Fumiaki, Phillips, Penny, Lisberg, Aaron E., Heist, Rebecca S.

Source: Journal of Clinical Oncology; 10/10/2023, Vol. 41 Issue 29, p4678-4687, 13p

Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist

Authors: Wong, Harvey ^*, Gould, Stephen E., Budha, Nageshwar, Darbonne, Walter C., Kadel, Edward E., III, La, Hank, Alicke, Bruno, Halladay, Jason S., Erickson, Rebecca, Portera, Chia, Tolcher, Anthony W., Infante, Jeffery R., Mamounas, Michael, Flygare, John A., Hop, Cornelis E.C.A., Fairbrother, Wayne J.

Source: In Drug Metabolism and Disposition December 2013 41(12):2104-2113

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

Authors: Infante, Jeffrey R., Papadopoulos, Kyriakos P., Bendell, Johanna C., Patnaik, Amita, Burris, Howard A., III, Rasco, Drew, Jones, Suzanne F., Smith, Lon, Cox, Donna S., Durante, Michael, Bellew, Kevin M., Park, Joohyun (Jennifer), Le, Ngocdiep T., Tolcher, Anthony W.

Source: In European Journal of Cancer June 2013 49(9):2077-2085

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours

Authors: Soria, Jean Charles, Massard, Christophe, Lazar, Vladimir, Ozoux, Marie-Laure, Mery-Mignard, Dominique, Deslandes, Antoine, Tolcher, Anthony W.

Source: In European Journal of Cancer May 2013 49(8):1799-1807

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Authors: Stathis, Anastasios, Tolcher, Anthony W., Wang, Judy S., Renouf, Daniel J., Chen, Lin-Chi, Suttner, Leah H., Freshwater, Tomoko, Webber, Andrea L., Nayak, Tapan, Siu, Lillian L.

Source: Investigational New Drugs; Jun2023, Vol. 41 Issue 3, p380-390, 11p

Subject Terms: SMALL molecules, CLINICAL drug trials, CLINICAL trials, DRUG tolerance, ORAL drug administration, METASTASIS, ANTINEOPLASTIC agents, INVESTIGATIONAL drugs, TUMOR classification, TRANSFERASES, DESCRIPTIVE statistics, RESEARCH funding, MITOGEN-activated protein kinases, TUMORS, PATIENT safety, PHARMACODYNAMICS

METHODS AND COMPOSITIONS FOR TREATING TUMOR DISEASES

A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.

Authors: Yap, Timothy A., Tolcher, Anthony W., Plummer, Elizabeth Ruth, Becker, Andreas, Fleuranceau-Morel, Patricia, Goddemeier, Thomas, Locatelli, Giuseppe, Gounaris, Ioannis, De Bono, Johann S.

Source: Journal of clinical oncology. 39(15 suppl):TPS3153-TPS3153

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173190741.0x000001&indx=1&recIds=ETOCvdc_100173190741.0x000001

Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.

Authors: Brody, Joshua, Thompson, John A., Tolcher, Anthony W., Kuhne, Michelle R., Huang, Xi (Rochelle), Kwan, Ellen, Petrarca, Michael, Dauki, Anees, Singh, Indrajeet, Rajakumaraswamy, Nishanthan, Kummar, Shivaani

Source: Journal of clinical oncology. 39(15 suppl):TPS3147-TPS3147

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173190661.0x000001&indx=1&recIds=ETOCvdc_100173190661.0x000001

PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.

Authors: Rodon Ahnert, Jordi, Perez, Cesar Augusto, Wong, Kit Man, Maitland, Michael L., Tsai, Frank, Berlin, Jordan, Liao, Kai Hsin, Wang, I-Ming, Markovtsova, Lada, Jacobs, Ira A, Cavazos, Nora, Li, Meng, Tolcher, Anthony W.

Source: Journal of clinical oncology. 39(15 suppl):3019-3019

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173188934.0x000001&indx=1&recIds=ETOCvdc_100173188934.0x000001